169 related articles for article (PubMed ID: 7986108)
1. [Preclinical studies for development of anti-cancer drugs: current and historical status and problems].
Okabe M; Kobayashi S; Hirata T; Nakano H; Ikegami J; Inoue K; Komuro T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():302-9. PubMed ID: 7986108
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Developing new agents for the treatment of childhood cancer.
Kurmasheva R; Morton C; Houghton PJ
Curr Opin Investig Drugs; 2005 Dec; 6(12):1215-27. PubMed ID: 16372407
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of preclinical toxicology studies for platinum anticancer drugs.
Clark DL; Andrews PA; Smith DD; DeGeorge JJ; Justice RL; Beitz JG
Clin Cancer Res; 1999 May; 5(5):1161-7. PubMed ID: 10353752
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
7. [The pharmacological properties of preparations from the aziridinyl triazine group].
Stukov AN; Filov VA; Kon'kov SA; Ivin BA
Eksp Klin Farmakol; 1996; 59(1):58-60. PubMed ID: 8704637
[TBL] [Abstract][Full Text] [Related]
8. [From the aspect of pre-clinical study of new anticancer candidate compounds].
Tsukagoshi S
Gan To Kagaku Ryoho; 1995 Apr; 22(5):599-602. PubMed ID: 7717709
[TBL] [Abstract][Full Text] [Related]
9. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.
Calvert H; Judson I; van der Vijgh WJ
Cancer Surv; 1993; 17():189-217. PubMed ID: 8137341
[TBL] [Abstract][Full Text] [Related]
10. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
11. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
12. Relation of preclinical toxicology to findings in early clinical trials.
Grieshaber CK; Marsoni S
Cancer Treat Rep; 1986 Jan; 70(1):65-72. PubMed ID: 3943115
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
Chun AW; Cosenza SC; Taft DR; Maniar M
Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
[TBL] [Abstract][Full Text] [Related]
14. Anticancer nitrosoureas: investigations on antineoplastic, toxic and neoplastic activities.
Eisenbrand G
IARC Sci Publ; 1984; (57):695-708. PubMed ID: 6533062
[TBL] [Abstract][Full Text] [Related]
15. The use of animal models in cancer drug discovery and development.
Curt GA
Stem Cells; 1994 Jan; 12(1):23-9. PubMed ID: 8142918
[TBL] [Abstract][Full Text] [Related]
16. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).
Giovanella BC; Stehlin JS; Hinz HR; Kozielski AJ; Harris NJ; Vardeman DM
Int J Oncol; 2002 Jan; 20(1):81-8. PubMed ID: 11743646
[TBL] [Abstract][Full Text] [Related]
18. Clinical and preclinical trials of isolated liver perfusion for advanced liver tumors: primary liver tumors.
Lowy AM; Curley SA
Surg Oncol Clin N Am; 1996 Apr; 5(2):429-41. PubMed ID: 9019362
[TBL] [Abstract][Full Text] [Related]
19. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
20. New approaches in preclinical and clinical pharmacokinetics.
Graham MA; Kaye SB
Cancer Surv; 1993; 17():27-49. PubMed ID: 8137345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
